User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Diagnosis and Management of Metastatic Prostate Cancer

Primary tabs

Tombal, Bertrand [UCL] Lecouvet, Frédéric [UCL]

With the widespread use of prostate-specific antigen (PSA) testing, metastatic prostate cancer is diagnosed less frequently. Consequently, not every newly diagnosed patient needs an imaging workshop. In patients with high-risk disease, the standard algorithm based on technetium bone scanning and computed tomography has clear limitations. In near future, magnetic resonance imaging and positron emission tomography should emerge as upfront imaging techniques. Androgen deprivation therapy remains the cornerstone treatment modality of metastatic prostate cancer. Despite many years of intensive use, many questions remain open, including the optimal timing of therapy, the optimal modality, and the role of intermittent treatment. Future strategies will include bone-targeted therapies, local treatment of oligo-metastatic disease, and combination of systemic therapies.

Document type Contribution à ouvrage collectif (Book Chapter) – Chapitre
Publication date 2014
Language Anglais
Host document Ashutosh K. Tewari, Peter Whelan, John D. Graham ; "Prostate Cancer: Diagnosis and clinical management"- p. 245-264 (ISBN : 978-111834737-9)
Publisher Wiley Blackwell ((United States) Hoboken, NJ)
Publication status Publié
Affiliations UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation
UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale
UCL - (SLuc) Service de radiologie
UCL - (SLuc) Service d'urologie
Keywords Androgen deprivation therapy ; Bone metastasis ; Magnetic Resonance Imaging ; Metastasis ; Prostate cancer
Links
  1. Ferlay Jacques, Shin Hai-Rim, Bray Freddie, Forman David, Mathers Colin, Parkin Donald Maxwell, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, 10.1002/ijc.25516
  2. Schröder Fritz H., Hugosson Jonas, Carlsson Sigrid, Tammela Teuvo, Määttänen Liisa, Auvinen Anssi, Kwiatkowski Maciej, Recker Franz, Roobol Monique J., Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC), 10.1016/j.eururo.2012.05.068
  3. Aus Gunnar, Bergdahl Svante, Lodding Pär, Lilja Hans, Hugosson Jonas, Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial, 10.1016/j.eururo.2006.07.012
  4. Soloway Mark S., Hardeman Stephen W., Hickey David, Todd Barbara, Soloway Scott, Raymond Jane, Moinuddin Mohammed, Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan, 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y
  5. Nørgaard Mette, Jensen Annette Østergaard, Jacobsen Jacob Bonde, Cetin Kara, Fryzek Jon P., Sørensen Henrik Toft, Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007), 10.1016/j.juro.2010.03.034
  6. Loberg Robert D., Logothetis Christopher J., Keller Evan T., Pienta Kenneth J., Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype, 10.1200/jco.2005.03.0841
  7. Heidenreich Axel, Bellmunt Joaquim, Bolla Michel, Joniau Steven, Mason Malcolm, Matveev Vsevolod, Mottet Nicolas, Schmid Hans-Peter, van der Kwast Theo, Wiegel Thomas, Zattoni Filliberto, EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease, 10.1016/j.eururo.2010.10.039
  8. Clinical practice guidelines in oncology. Prostate cancer. V.1. 2013. Available at http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf
  9. RANA A., KARAMANIS K., LUCAS M. G., CHISHOLM G. D., Identification of Metastatic Disease by T Category, Gleason Score and Serum PSA Level in Patients with Carcinoma of the Prostate, 10.1111/j.1464-410x.1992.tb15528.x
  10. Briganti Alberto, Passoni Niccolò, Ferrari Matteo, Capitanio Umberto, Suardi Nazareno, Gallina Andrea, Pozzo Luigi Filippo Da, Picchio Maria, Di Girolamo Valerio, Salonia Andrea, Gianolli Liugi, Messa Cristina, Rigatti Patrizio, Montorsi Francesco, When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool , 10.1016/j.eururo.2009.12.023
  11. Pound Charles R., Natural History of Progression After PSA Elevation Following Radical Prostatectomy, 10.1001/jama.281.17.1591
  12. Hövels A.M., Heesakkers R.A.M., Adang E.M., Jager G.J., Strum S., Hoogeveen Y.L., Severens J.L., Barentsz J.O., The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, 10.1016/j.crad.2007.05.022
  13. Barentsz Jelle O., Richenberg Jonathan, Clements Richard, Choyke Peter, Verma Sadhna, Villeirs Geert, Rouviere Olivier, Logager Vibeke, Fütterer Jurgen J., ESUR prostate MR guidelines 2012, 10.1007/s00330-011-2377-y
  14. Heesakkers Roel AM, Hövels Anke M, Jager Gerrit J, van den Bosch Harrie CM, Witjes J Alfred, Raat Hein PJ, Severens Johan L, Adang Eddy MM, van der Kaa Christina Hulsbergen, Fütterer Jurgen J, Barentsz Jelle, MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study, 10.1016/s1470-2045(08)70203-1
  15. Schiavina Riccardo, Scattoni Vincenzo, Castellucci Paolo, Picchio Maria, Corti Barbara, Briganti Alberto, Franceschelli Alessandro, Sanguedolce Francesco, Bertaccini Alessandro, Farsad Moshen, Giovacchini Giampiero, Fanti Stefano, Grigioni Walter Franco, Fazio Ferruccio, Montorsi Francesco, Rigatti Patrizio, Martorana Giuseppe, 11C-Choline Positron Emission Tomography/Computerized Tomography for Preoperative Lymph-Node Staging in Intermediate-Risk and High-Risk Prostate Cancer: Comparison with Clinical Staging Nomograms, 10.1016/j.eururo.2008.04.030
  16. Budiharto Tom, Joniau Steven, Lerut Evelyne, Van den Bergh Laura, Mottaghy Felix, Deroose Christophe M., Oyen Raymond, Ameye Filip, Bogaerts Kris, Haustermans Karin, Van Poppel Hendrik, Prospective Evaluation of 11C-Choline Positron Emission Tomography/Computed Tomography and Diffusion-Weighted Magnetic Resonance Imaging for the Nodal Staging of Prostate Cancer with a High Risk of Lymph Node Metastases, 10.1016/j.eururo.2011.01.015
  17. Condon B. R., Buchanan R., Garvie N. W., Ackery D. M., Fleming J., Taylor D., Hawkes D., Goddard B. A., Assessment of progression of secondary bone lesions following cancer of the breast or prostate using serial radionuclide imaging, 10.1259/0007-1285-54-637-18
  18. Eustace S, Tello R, DeCarvalho V, Carey J, Wroblicka J T, Melhem E R, Yucel E K, A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases., 10.2214/ajr.169.6.9393186
  19. Daldrup-Link Heike E., Franzius Christiane, Link Thomas M., Laukamp Daniela, Sciuk Joachim, Jürgens Heribert, Schober Otmar, Rummeny Ernst J., Whole-Body MR Imaging for Detection of Bone Metastases in Children and Young Adults : Comparison with Skeletal Scintigraphy and FDG PET, 10.2214/ajr.177.1.1770229
  20. Jacobson Arnold F., Fogelman Ignac, Bone scanning in clinical oncology: does it have a future?, 10.1007/s002590050287
  21. Gosfield, J Nucl Med, 34, 2191 (1993)
  22. Venkitaraman Ramachandran, Sohaib Aslam, Cook Gary, MRI or Bone Scan or Both for Staging of Prostate Cancer?, 10.1200/jco.2007.14.3875
  23. Schirrmeister Holger, Kühn Thorsten, Guhlmann Albrecht, Santjohanser Claudia, Hörster Thomas, Nüssle Karin, Koretz Karin, Glatting Gerhard, Rieber Andrea, Kreienberg Rolf, Buck Andreas C, Reske Sven N, Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures, 10.1007/s002590000448
  24. Ghanem N., Uhl M., Brink I., Schäfer O., Kelly T., Moser E., Langer M., Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone, 10.1016/j.ejrad.2005.01.016
  25. Beheshti Mohsen, Vali Reza, Waldenberger Peter, Fitz Friedrich, Nader Michael, Loidl Wolfgang, Broinger Gabriele, Stoiber Franz, Foglman Ignac, Langsteger Werner, Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study, 10.1007/s00259-008-0788-z
  26. Haubold-Reuter B.G., Duewell S., Schilcher B.R., Marincek B., Schulthess G.K.V., The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study, 10.1007/bf00173484
  27. Schirrmeister, J Nucl Med, 40, 1623 (1999)
  28. Tombal Bertrand, Rezazadeh Afshin, Therasse Patrick, Van Cangh Paul J., Vande Berg Bruno, Lecouvet Frédéric E., Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases, 10.1002/pros.20280
  29. Lecouvet Frédéric E., Geukens Daphné, Stainier Annabelle, Jamar François, Jamart Jacques, d'Othée Bertrand Janne, Therasse Patrick, Berg Bruno Vande, Tombal Bertrand, Magnetic Resonance Imaging of the Axial Skeleton for Detecting Bone Metastases in Patients With High-Risk Prostate Cancer: Diagnostic and Cost-Effectiveness and Comparison With Current Detection Strategies, 10.1200/jco.2006.09.2940
  30. Lecouvet Frédéric E., El Mouedden Jawad, Collette Laurence, Coche Emmanuel, Danse Etienne, Jamar François, Machiels Jean-Pascal, Vande Berg Bruno, Omoumi Patrick, Tombal Bertrand, Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer?, 10.1016/j.eururo.2012.02.020
  31. Lecouvet F. E., Simon M., Tombal B., Jamart J., Vande Berg B. C., Simoni P., Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa), 10.1007/s00330-010-1879-3
  32. Venkitaraman R, Cook GJR, Dearnaley DP, Parker CC, Khoo V, Eeles R, Huddart RA, Horwich A, Sohaib SA, Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer, 10.1111/j.1754-9485.2009.02070.x
  33. Eschmann, Nuklearmedizin, 46, 161 (2007)
  34. Khoo Michael M. Y., Tyler Philippa A., Saifuddin Asif, Padhani Anwar R., Diffusion-weighted imaging (DWI) in musculoskeletal MRI: a critical review, 10.1007/s00256-011-1106-6
  35. Huggins, Cancer Res, 27, 1925 (1967)
  36. Heidenreich Axel, Consensus Criteria for the Use of Magnetic Resonance Imaging in the Diagnosis and Staging of Prostate Cancer: Not Ready for Routine Use, 10.1016/j.eururo.2011.01.013
  37. The Veterans Administration Co-operative Urological Research Group, Surg Gynecol Obstet, 124, 1011 (1967)
  38. Byar David P., The veterans administration cooperative urological research group's studies of cancer of the prostate, 10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c
  39. Byar, Bull Cancer (Paris), 67, 477 (1980)
  40. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial, 10.1046/j.1464-410x.1997.d01-6840.x
  41. Nair, Cochrane Database Syst Rev, CD003506 (2002)
  42. Isaacs John T., The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer, 10.1002/pros.2990050102
  43. Studer Urs E., Collette Laurence, Whelan Peter, Albrecht Walter, Casselman Jacques, de Reijke Theo, Knönagel Hartmut, Loidl Wolfgang, Isorna Santiago, Sundaram Subramanian K., Debois Muriel, Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891), 10.1016/j.eururo.2007.12.032
  44. Schally A.V., Arimura A., Baba Y., Nair R.M.G., Matsuo H., Redding T.W., Debeljuk L., White W.F., Isolation and properties of the FSH and LH-releasing hormone, 10.1016/0006-291x(71)90766-2
  45. , Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer, 10.1056/nejm198411153112004
  46. Vogelzang Nicholas J., Chodak Gerald W., Soloway Mark S., Block Norman L., Schellhammer Paul F., Smith Joseph A., Caplan Richard J., Kennealey Gerard T., Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial, 10.1016/s0090-4295(99)80197-6
  47. KAISARY A. V., TYRRELL C. J., PEELING W. B., GRIFFITHS K., Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma, 10.1111/j.1464-410x.1991.tb15195.x
  48. Thompson, Rev Urol, 3, S10 (2001)
  49. Kuhn Jean-Marc, Billebaud Thierry, Navratil Henri, Moulonguet Albert, Fiet Jean, Grise Philippe, Louis Jean-François, Costa Pierre, Husson Jean-Marc, Dahan Robert, Bertagna Christine, Edelstein Richard, Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide), 10.1056/nejm198908173210701
  50. Crawford E. David, Eisenberger Mario A., McLeod David G., Spaulding Joseph T., Benson Ralph, Dorr F. Andrew, Blumenstein Brent A., Davis Marilyn A., Goodman Phyllis J., A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma, 10.1056/nejm198908173210702
  51. Klotz Laurence, Boccon-Gibod Laurent, Shore Neal D., Andreou Cal, Persson Bo-Eric, Cantor Per, Jensen Jens-Kristian, Olesen Tine Kold, Schröder Fritz H., The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer, 10.1111/j.1464-410x.2008.08183.x
  52. Tombal Bertrand, Miller Kurt, Boccon-Gibod Laurent, Schröder Fritz, Shore Neal, Crawford E. David, Moul Judd, Jensen Jens-Kristian, Kold Olesen Tine, Persson Bo-Eric, Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics, 10.1016/j.eururo.2009.11.029
  53. Schröder Fritz H., Tombal Bertrand, Miller Kurt, Boccon-Gibod Laurent, Shore Neal D., Crawford E. David, Moul Judd, Olesen Tine Kold, Persson Bo-Eric, Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study : ALP LEVELS IN PATIENTS WITH PROSTATE CANCER RECEIVING DEGARELIX OR LEUPROLIDE, 10.1111/j.1464-410x.2009.08981.x
  54. Thorpe, Eur Urol, 29, 47 (1996)
  55. Tyrrell C.J., Kaisary A.V., Iversen P., Anderson J.B., Baert L., Tammela T., Chamberlain M., Webster A., Blackledge G., A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer, 10.1159/000019634
  56. Mottet Nicolas, Bellmunt Joaquim, Bolla Michel, Joniau Steven, Mason Malcolm, Matveev Vsevolod, Schmid Hans-Peter, Van der Kwast Theo, Wiegel Thomas, Zattoni Filiberto, Heidenreich Axel, EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer, 10.1016/j.eururo.2011.01.025
  57. Schmitt, Cochrane Database Syst Rev (2000)
  58. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials, 10.1016/s0140-6736(00)02163-2
  59. Sylvester Richard J., Denis Louis, de Voogt Herman, The Importance of Prognostic Factors in the Interpretation of Two EORTC Metastatic Prostate Cancer Trials, 10.1159/000019545
  60. Akakura Koichiro, Bruchovsky Nicholas, Goldenberg S. Larry, Rennie Paul S., Buckley Anne R., Sullivan Lorne D., Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen, 10.1002/1097-0142(19930501)71:9<2782::aid-cncr2820710916>3.0.co;2-z
  61. Bhandari Manish S., Crook Juanita, Hussain Maha, Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?, 10.1200/jco.2005.03.2557
  62. Calais da Silva Fernando E.C., Bono Aldo V., Whelan Peter, Brausi Maurizio, Marques Queimadelos Anton, Martin Jose A. Portillo, Kirkali Ziya, Calais da Silva Fernando M.V., Robertson Chris, Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group, 10.1016/j.eururo.2009.02.016
  63. Salonen Arto J., Taari Kimmo, Ala-Opas Martti, Viitanen Jouko, Lundstedt Seppo, Tammela Teuvo L.J., The FinnProstate Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer, 10.1016/j.juro.2012.01.122
  64. Salonen Arto J., Taari Kimmo, Ala-Opas Martti, Viitanen Jouko, Lundstedt Seppo, Tammela Teuvo L.J., Advanced Prostate Cancer Treated with Intermittent or Continuous Androgen Deprivation in the Randomised FinnProstate Study VII: Quality of Life and Adverse Effects, 10.1016/j.eururo.2012.07.040
  65. Hussain, J Clin Oncol, 30 (2012)
  66. Tombal Bertrand, A Holistic Approach to Androgen Deprivation Therapy: Treating the Cancer without Hurting the Patient, 10.1159/000251174
  67. Keating N. L., O'Malley A. J., Freedland S. J., Smith M. R., Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer, 10.1093/jnci/djp404
  68. Smith Matthew R., Egerdie Blair, Toriz Narciso Hernández, Feldman Robert, Tammela Teuvo L.J., Saad Fred, Heracek Jiri, Szwedowski Maciej, Ke Chunlei, Kupic Amy, Leder Benjamin Z., Goessl Carsten, Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer, 10.1056/nejmoa0809003
  69. Smith Matthew R., O’Malley A. James, Keating Nancy L., Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?, 10.1111/j.1464-410x.2008.07707.x
  70. Smith Matthew R., Lee Hang, Nathan David M., Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer, 10.1210/jc.2005-2507
  71. Smith Matthew R., Lee Won Chan, Brandman Jane, Wang Qin, Botteman Marc, Pashos Chris L., Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer, 10.1200/jco.2004.00.6908
  72. Dearnaley D. P., A Double-Blind, Placebo-Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial), 10.1093/jnci/djg038
  73. Dearnaley David P, Mason Malcolm D, Parmar Mahesh KB, Sanders Karen, Sydes Matthew R, Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials, 10.1016/s1470-2045(09)70201-3
  74. Sydes Matthew R, Parmar Mahesh KB, Mason Malcolm D, Clarke Noel W, Amos Claire, Anderson John, de Bono Johann, Dearnaley David P, Dwyer John, Green Charlene, Jovic Gordana, Ritchie Alastair WS, Russell J Martin, Sanders Karen, Thalmann George, James Nicholas D, Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial, 10.1186/1745-6215-13-168
Bibliographic reference Tombal, Bertrand ; Lecouvet, Frédéric. Diagnosis and Management of Metastatic Prostate Cancer. In: Ashutosh K. Tewari, Peter Whelan, John D. Graham, Prostate Cancer: Diagnosis and clinical management, Wiley Blackwell  : (United States) Hoboken, NJ 2014, p. 245-264
Permanent URL http://hdl.handle.net/2078.1/186661